ImmunityBio Shares Jump After EU Clears ANKTIVA for BCG-Unresponsive Bladder Cancer
ImmunityBio stock rose sharply after the European Commission granted conditional marketing authorization for ANKTIVA in combination with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The approval covers the 27 EU member states plus Iceland, Norway and Liechtenstein, bringing ANKTIVA’s regulatory reach to 3…